Compare 10X Genomics Inc (TXG) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Under Armour Inc Class A — how do they compare? 10X Genomics Inc trades at $47.2 (market cap $5.48B), while Under Armour Inc Class A trades at $7.18 (market cap $3.07B). The key difference: 10X Genomics Inc is the larger of the two by market cap, and 10X Genomics Inc is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals.
| TXG | UA | |
|---|---|---|
Market Cap | $5.48B | $3.07B |
Sector | Health | Consumer Cyclical |
52-Week High | $45.80 | $7.88 |
52-Week Low | $11.34 | $3.96 |
Enterprise Value | $5.02B | $4.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.
The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.
Under Armour (UA) trades at $7.13, down 2.06% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $201.27 million in fiscal 2025, with negative margins and cash flow, though revenue remains substantial at $5.16 billion. Recent news highlights a new Dodge collaboration and an upcoming Q1 2027 earnings call on August 7, 2026.
Outlook is mixed: analyst consensus leans slightly bullish with 40% buy ratings, but fundamental challenges persist including declining revenue projections and negative profitability. Key risks include execution of the business reset and competitive pressures. The stock presents a turnaround opportunity but requires careful monitoring of earnings and margin improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
